No Data
Chimerix Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Chimerix Analyst Ratings
Chimerix's Dordaviprone Shows Promising Efficacy in H3 K27M-mutant Diffuse Glioma With $11 Price Target
Press Release: Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript Summary
Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript